Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22162343 | 0.81 | MEN1 (0.38) | SMN1; SMN2USP2KMT2AALDH1A1MEN1 | |
| SCHEMBL29018459 | 0.80 | USP2 (0.40) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL22145206 | 0.80 | USP2 (0.40) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL4161903 | 0.75 | CTSK (0.37) | HPGDKMT2AALDH1A1MEN1 | |
| SCHEMBL4168739 | 0.72 | GCK (0.34) | — | |
| SCHEMBL7639692 | 0.72 | USP2 (0.37) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL20286471 | 0.71 | HPGD (0.41) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL23501579 | 0.70 | KMT2A (0.41) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL18269631 | 0.70 | USP2 (0.40) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL22162776 | 0.70 | FPR2 (0.43) | SMN1; SMN2HPGDNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236841-B2 | Fused heterocycle derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-20090239853-A1 | Fused heterocycle derivative | KYOWA KIRIN CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-2070927-A1 | FUSED HETEROCYCLIC DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239853-A1 | Fused heterocycle derivative | NR5A2, CBR3, NR3C2 | SMN1; SMN2 3284/4885USP2 4685/4885HPGD 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.